Skip to main content
SpringerLink
Log in

Venous thromboembolism risk and erythropoiesis-stimulating agents for the treatment of cancer-associated anemia: a meta-analysis

  • Research Article
  • Published:
Tumor Biology

Abstract

Erythropoiesis-stimulating agents (ESAs) reduce anemia in patients with cancer and could improve their quality of life, but ESA-related safety concerns exist. To evaluate the overall risk of venous thromboembolism (VTE) associated with the use of ESAs, a systematic review and meta-analysis of published randomized controlled trials (RCTs) was performed. The databases of PubMed and Web of Science and the abstracts presented at the American Society of Clinical Oncology conferences were searched to identify relevant clinical trials. Summary incidence rates, relative risks (RRs), and 95 % confidence intervals (CIs) were calculated. A total of 12,115 patients with a variety of cancer types from 51 RCTs were identified and included in the meta-analysis. Among patients receiving ESAs, the summary incidence of all-grade VTE was 7.78 %. Patients with cancer who received ESAs had increased VTE risks (484 events among 6,301 patients treated with ESA vs. 276 events among 5,814 control patients; RR = 1.75 [95 % CI, 1.50–2.05]). The highest risk of VTE was found in patients with ovarian and cervical cancers (RR = 2.45 [CI = 1.12–5.33]). The VTE risk among hematologic malignancies was higher than that among solid tumors. The administration of ESAs was significantly associated with an increased risk of developing VTE in cancer patients receiving these drugs. The risks of VTE may vary with various tumor types, including hematologic malignancies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8

Similar content being viewed by others

References

  1. Bokemeyer C, Oechsle K, Hartmann J-T. Anaemia in cancer patients: pathophysiology, incidence and treatment. Eur J Clin Invest. 2005;35 Suppl 3:26–31.

    Article  PubMed  Google Scholar 

  2. Ludwig H, van Belle S, Barrett-Lee P, Birgegard G, Bokemeyer C, Gascon P, et al. The European Cancer Anemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anemia in cancer patients. Eur J Cancer. 2004;40:2293–306.

    Article  PubMed  Google Scholar 

  3. Caro JJ, Salas M, Ward A, Goss G. Anemia as an independent prognostic factor for survival in patients with cancer: a systematic, quantitative review. Cancer. 2001;91:2214–21.

    Article  CAS  PubMed  Google Scholar 

  4. Seidenfeld J, Piper M, Flamm C, et al. Epoetin treatment of anemia associated with cancer therapy: a systematic review and meta-analysis of controlled clinical trials. J Natl Cancer Inst. 2001;93:1204–14.

    Article  CAS  PubMed  Google Scholar 

  5. Bohlius J, Wilson J, Seidenfeld J, et al. Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst. 2006;98:708–14.

    Article  CAS  PubMed  Google Scholar 

  6. Wilson J, Yao GL, Raftery J, et al. A systematic review and economic evaluation of epoetin alfa, epoetin beta and darbepoetin alfa in anaemia associated with cancer, especially that attributable to cancer treatment. Health Technol Assess. 2007;11:1–220.

    CAS  PubMed  Google Scholar 

  7. Minton O, Richardson A, Sharpe M, Hotopf M, Stone P. A systematic review and meta-analysis of the pharmacological treatment of cancer-related fatigue. J Natl Cancer Inst. 2008;100:1155–66.

    Article  CAS  PubMed  Google Scholar 

  8. Bennett CL, Silver SM, Djulbegovic B, et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA. 2008;299:914–24.

    Article  CAS  PubMed  Google Scholar 

  9. Henke M, Mattern D, Pepe M, et al. Do erythropoietin receptors on cancer cells explain unexpected clinical findings? J Clin Oncol. 2006;24:4708–13.

    Article  CAS  PubMed  Google Scholar 

  10. FDA briefing document. Safety concerns associated with Aranesp (darbepoetin alfa) Amgen, Inc. and Procrit (epoetin alfa) Ortho Biotech, L.P., for the treatment of anemia associated with cancer chemotherapy. Hearings before the Subcommittee on Oncologic Drugs Advisory Committee, Center for Drug Evaluation and Research. http://www.fda.gov/ohrms/dockets/ac/04/briefing/4037B2_04_FDA-Aranesp-Procrit.htm#_ednref45 (2008).

  11. Brower V. ESAs further restricted, but debate continues. J Natl Cancer Inst. 2008;100:1344–51.

    Article  PubMed  Google Scholar 

  12. The Cochrane Collaboration. Review Manager (RevMan) [computer program]. Version 5.0. Copenhagen: The Nordic Cochrane Centre; 2008.

  13. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88.

    Article  CAS  PubMed  Google Scholar 

  14. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539–58.

    Article  PubMed  Google Scholar 

  15. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50:1088–101.

    Article  CAS  PubMed  Google Scholar 

  16. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–34.

    Article  CAS  PubMed  Google Scholar 

  17. Aapro M, Leonard RC, Barnadas A, Marangolo M, Untch M, Malamos N, et al. Effect of once-weekly epoetin beta on survival in patients with metastatic breast cancer receiving anthracycline- and/or taxane-based chemotherapy: results of the Breast Cancer–Anemia and the Value of Erythropoietin (BRAVE) study. J Clin Oncol. 2008;26(4):592–8.

    Article  CAS  PubMed  Google Scholar 

  18. Amgen DA 145 Study. April 19, 2007. http://wwwext.amgen.com/media/media_pr_detail.jsp?year=2007&releaseID=987476 (2008).

  19. Abels R. Erythropoietin for anaemia in cancer patients. Eur J Cancer. 1993;29A suppl 2:S2–8.

    Article  PubMed  Google Scholar 

  20. Blohmer JU, Paepke S, Sehouli J, Boehmer D, Kolben M, Würschmidt F, et al. Randomized phase III trial of sequential adjuvant chemoradiotherapy with or without erythropoietin alfa in patients with high-risk cervical cancer: results of the NOGGO-AGO intergroup study. J Clin Oncol. 2011;29(28):3791–7.

    Article  CAS  PubMed  Google Scholar 

  21. Bamias A, Aravantinos G, Kalofonos C, et al. Prevention of anemia in patients with solid tumors receiving platinum-based chemotherapy by recombinant human erythropoietin (rHuEpo): a prospective, open label, randomized trial by the Hellenic Cooperative Oncology Group. Oncology. 2003;64(2):102–10.

    Article  CAS  PubMed  Google Scholar 

  22. Cabanillas ME, Kantarjian H, Thomas DA, Mattiuzzi GN, Rytting ME, Bruera E, et al. Epoetin alpha decreases the number of erythrocyte transfusions in patients with acute lymphoblastic leukemia, lymphoblastic lymphoma, and Burkitt leukemia/lymphoma: results of a randomized clinical trial. Cancer. 2012;118(3):848–55.

    Article  CAS  PubMed  Google Scholar 

  23. Cascinu S, Fedeli A, Del Ferro E, Luzi Fedeli S, Cat-alano G. Recombinant human erythropoietin treatment in cisplatin-associated anemia: a randomized, double-blind trial with placebo. J Clin Oncol. 1994;12(5):1058–62.

    CAS  PubMed  Google Scholar 

  24. Case Jr DC, Bukowski RM, Carey RW, et al. Recombinant human erythropoietin therapy for anemic cancer patients on combination chemotherapy. J Natl Cancer Inst. 1993;85(10):801–6.

    Article  PubMed  Google Scholar 

  25. Dammacco F, Castoldi G, Rodjer S. Efficacy of epoetin alfa in the treatment of anaemia of multiple myeloma. Br J Haematol. 2001;113(1):172–9.

    Article  CAS  PubMed  Google Scholar 

  26. Debus JHS, Morr H, Mezger J, Sebastian M, Angermund R, Drings P. Epoetin alfa (EPO) and survival in patients with non-resectable NSCLC—interim results. German Medical Science. http://www.egms.de/en/meetings/dkk2006/06dkk257.shtml (2007).

  27. FDA briefing document. May 10, 2007: Oncologic Drugs Advisory Committee. Continuing reassessment of the risks of erythropoiesis-stimulating agents (ESAs) administered for the treatment of anemia associated with cancer chemotherapy. http://www.fda.gov/ohrms/dockets/ac/07/briefing/2007-4301b2-02-FDA.pdf (2008).

  28. Fujisaka Y, Sugiyama T, Saito H, Nagase S, Kudoh S, Endo M, et al. Randomised, phase III trial of epoetin-β to treat chemotherapy-induced anaemia according to the EU regulation. Br J Cancer. 2011;105(9):1267–72.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  29. Gupta S, Singh PK, Bisth SS, Bhatt ML, Pant M, Gupta R, et al. Role of recombinant human erythropoietin in patients of advanced cervical cancer treated “by chemoradiotherapy”. Cancer Biol Ther. 2009;8(1):13–7.

    Article  CAS  PubMed  Google Scholar 

  30. Grote T, Yeilding AL, Castillo R, et al. Efficacy and safety analysis of epoetin alfa in patients with small-cell lung cancer: a randomized, double-blind, placebo-controlled trial. J Clin Oncol. 2005;23(36):9377–86.

    Article  CAS  PubMed  Google Scholar 

  31. Gordon DH, Nichols G, Ben-Jacob A, et al. Treating anemia of cancer with darbepoetin alfa adminis-tration every 4 weeks: final results from a phase 2, randomized, double-blind, placebo-controlled study in cancer patients not receiving chemotherapy and/or radiotherapy. Presented at American Society of Hematology; December 9, 2006; Orlando, FL; Abstract 1304.

  32. Hernandez E, Ganly P, Charu V, Dibenedetto J, Tomita D, Lillie T, et al. Randomized, double-blind, placebo-controlled trial of every-3-week darbepoetin alfa 300 micrograms for treatment of chemotherapy-induced anemia. Curr Med Res Opin. 2009;25(9):2109–20.

    Article  CAS  PubMed  Google Scholar 

  33. Hoskin PJ, Robinson M, Slevin N, Morgan D, Harrington K, Gaffney C. Effect of epoetin alfa on survival and cancer treatment-related anemia and fatigue in patients receiving radical radiotherapy with curative intent for head and neck cancer. J Clin Oncol. 2009;27(34):5751–6.

    Article  CAS  PubMed  Google Scholar 

  34. Henke M, Laszig R, Rube C, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet. 2003;362(9392):1255–60.

    Article  CAS  PubMed  Google Scholar 

  35. Henry DH, Abels RI. Recombinant human erythropoietin in the treatment of cancer and chemotherapy-induced anemia: results of double-blind and open-label follow-up studies. Semin Oncol. 1994;21 suppl 3:21–8.

    CAS  PubMed  Google Scholar 

  36. Leyland-Jones B, Semiglazov V, Pawlicki M, et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol. 2005;23(25):5960–72.

    Article  CAS  PubMed  Google Scholar 

  37. Littlewood TJ, Bajetta E, Nortier JW, Vercam-men E, Rapoport B. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol. 2001;19(11):2865–74.

    CAS  PubMed  Google Scholar 

  38. Machtay M, Pajak TF, Suntharalingam M, et al. Radiotherapy with or without erythropoietin for anemic patients with head and neck cancer: a randomized trial of the radiation therapy oncology group (RTOG 99-03). Int J Radiat Oncol Biol Phys. 2007;69(4):1008–17.

    Article  CAS  PubMed  Google Scholar 

  39. Osterborg A, Boogaerts MA, Cimino R, et al. Recombinant human erythropoietin in transfusion-dependent anemic patients with multiple myeloma and non-Hodgkin’s lymphoma—a randomized multicenter study. The European Study Group of Erythropoietin (Epoetin Beta) Treatment in Multiple Myeloma and Non-Hodgkin’s Lymphoma. Blood. 1996;87(7):2675–82.

    CAS  PubMed  Google Scholar 

  40. Osterborg A, Brandberg Y, Hedenus M. Impact of epoetin-beta on survival of patients with lymphoproliferative malignancies: long-term follow up of a large randomized study. Br J Haematol. 2005;129(2):206–9.

    Article  PubMed  Google Scholar 

  41. Pirker R, Ramlau RA, Schuette W, Zatloukal P, Ferreira I, Lillie T, et al. Safety and efficacy of darbepoetin alpha in previously untreated extensive-stage small-cell lung cancer treated with platinum plus etoposide. J Clin Oncol. 2008;26(14):2342–9.

    Article  CAS  PubMed  Google Scholar 

  42. Pronzato P, Cortesi E, van der Rijt CC, Bols A, Moreno-Nogueira JA, de Oliveira CF, et al. Epoetin alfa improves anemia and anemia-related, patient-reported outcomes in patients with breast cancer receiving myelotoxic chemotherapy: results of a European, multicenter, randomized, controlled trial. Oncologist. 2010;15(9):935–43.

    Article  CAS  PubMed  Google Scholar 

  43. Razzouk BI, Hockenberry M, Hinds PS, Rackoff W, Hord JD. A double-blind, placebo-controlled study of once-weekly epoetin alfa in children with cancer undergoing myelosuppressive chemotherapy. J Clin Oncol. 22:14S. June 5, 2004. Presented at the 40th Annual Meeting of the American Society of Clinical Oncology; June 5–8, 2004; New Orleans, LA; Abstract 8527.

  44. Rose ERK, Revicki D, Brown R, Reblando J. Clinical and health status assessments in anemic chronic lymphocytic leukemia (CLL) patients treated with epoetin alfa (EPO). Blood. 1994;4 suppl 1:526a.

    Google Scholar 

  45. Rosenzweig MQ, Bender CM, Lucke JP, Yasko JM, Brufsky AM. The decision to prematurely terminate a trial of R-HuEPO due to thrombotic events. J Pain Symptom Manage. 2004;27(2):185–90.

    Article  PubMed  Google Scholar 

  46. Ray-Coquard I, Dussart S, Goillot C, Mayeur D, Debourdeau P, Ghesquieres H, et al. A risk model for severe anemia to select cancer patients for primary prophylaxis with epoetin alpha: a prospective randomized controlled trial of the ELYPSE study group. Ann Oncol. 2009;20(6):1105–12.

    Article  CAS  PubMed  Google Scholar 

  47. Savonije JVGC, Van Bochove A, Pinedo H, Giaccone G. Early intervention with epoetin-alfa during platinum-based chemotherapy. J Clin Oncol. 22:14S. June 5, 2004. Presented at the 40th Annual Meeting of the American Society of Clinical Oncology; June 5–8, 2004; New Orleans, LA; Abstract 8111.

  48. Smith Jr RE, Tchekmedyian NS, Chan D, et al. A dose- and schedule-finding study of darbepoetin alpha for the treatment of chronic anaemia of cancer. Br J Cancer. 2003;88(12):1851–8.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  49. Ten Bokkel Huinink WW, de Swart CA, van Toorn DW, et al. Controlled multicentre study of the influence of subcutaneous recombinant human erythropoietin on anaemia and transfusion dependency in patients with ovarian carcinoma treated with platinum-based chemotherapy. Med Oncol. 1998;15(3):174–82.

    Article  PubMed  Google Scholar 

  50. Thatcher N, De Campos ES, Bell DR, et al. Epoetin alpha prevents anaemia and reduces transfusion requirements in patients undergoing primarily platinum-based chemotherapy for small cell lung cancer. Br J Cancer. 1999;80(3–4):396–402.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  51. Throuvalas N, Antonadou D, Boufi M, Lavey R. Erythropoietin decreases transfusion requirements during radiochemotherapy. Paper presented at the 36th Annual Meeting of the American Society of Clincial Oncology; May 20–24, 2000; New Orleans, LA; Abstract 1558.

  52. Tsuboi M, Ezaki K, Tobinai K, Ohashi Y, Saijo N. Weekly administration of epoetin beta for chemotherapy-induced anemia in cancer patients: results of a multicenter, phase III, randomized, double-blind, placebo-controlled study. Jpn J Clin Oncol. 2009;39(3):163–8.

    Article  PubMed  Google Scholar 

  53. Untch M, von Minckwitz G, Konecny GE, Conrad U, Fett W, Kurzeder C, et al. PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel, and CMF versus a standard-dosed epirubicin–cyclophosphamide followed by paclitaxel with or without darbepoetin alfa in primary breast cancer—outcome on prognosis. Ann Oncol. 2011;22(9):1999–2006.

    Article  CAS  PubMed  Google Scholar 

  54. Vadhan-Raj SSJ, Crane C, Buesos-Ramos CE, et al. Randomized, double-blind, placebo-controlled trial of epoetin alfa (Procrit) in patients with rectal and gastric cancer undergoing chemo-radiotherapy (CT/RT) followed by surgery: early termination o f the trial due to increased incidence of thrombo-embolic events (TEE). Blood 104:797a. Presented at the 46th Annual Meeting of the American Sociey of Hematology; December 4–7, 2004; San Diego, CA; Abstract 2915.

  55. Vansteenkiste J, Pirker R, Massuti B, et al. Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J N atl Cancer Inst. 2002;94(16):1211–20.

    Article  CAS  Google Scholar 

  56. Witzig TE, Silberstein PT, Loprinzi CL, et al. Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy. J Clin Oncol. 2005;23(12):2606–17.

    Article  CAS  PubMed  Google Scholar 

  57. Wright JR, Ung YC, Julian JA, et al. Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. J Clin Oncol. 2007;25(9):1027–32.

    Article  CAS  PubMed  Google Scholar 

  58. Welch RS, James RD, Wilkinson PM, Belli F, Cowan RA. Recombinant human erythropoietin and platinum-based chemotherapy in advanced ovarian cancer. Cancer J Sci Am. 1995;1(4):261–6.

    CAS  PubMed  Google Scholar 

  59. Wilkinson PM, Ntonopoulos AM, Lahousen M, Lind M, Kosmidis P. Epoetin alfa in platinum-treated ovarian cancer patients: results of a multinational, multi-centre, randomised trial. Br J Cancer. 2006;94(7):947–54.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  60. Weigang-Köhler K, Vetter A, Thyroff-Friesinger U. HX575, recombinant human epoetin alfa, for the treatment of chemotherapy-associated symptomatic anaemia in patients with solid tumours. Onkologie. 2009;32(4):168–74.

    Article  PubMed  Google Scholar 

  61. Prasad HK, Nelsen D, Siegel ER, Raval G, Rajan S, Hutchins LF. Risk of venous thromboembolism (VTE) in breast cancer patients receiving erythropoietin for chemotherapy-induced anemia: A Tertiary Cancer Center experience from the University of Arkansas for Medical Sciences. J Clin Oncol 2008;26:15S. May 20 Supplement; Abstract 20621.

    Google Scholar 

  62. Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost. 2007;5(3):632–4.

    Article  CAS  PubMed  Google Scholar 

  63. Hardee ME, Arcasoy MO, Blackwell KL, Kirkpa-trick JP, Dewhirst MW. Erythropoietin biology in cancer. Clin Cancer Res. 2006;12(2):332–9.

    Article  CAS  PubMed  Google Scholar 

  64. Hardee ME, Rabbani ZN, Arcasoy MO, et al. Erythropoietin inhibits apoptosis in breast cancer cells via an Akt-dependent pathway without modulating in vivo chemosensitivity. Mol Cancer Ther. 2006;5(2):356–61.

    Article  CAS  PubMed  Google Scholar 

  65. Acs G, Acs P, Beckwith SM, et al. Erythropoietin and erythropoietin receptor expression in human cancer. Cancer Res. 2001;61(9):3561–5.

    CAS  PubMed  Google Scholar 

  66. Lai SY, Childs EE, Xi S, et al. Erythropoietin-mediated activation of JAK-STAT signaling contributes to cellular invasion in head and neck squamous cell carcinoma. Oncogene. 2005;24(27):4442–9.

    Article  CAS  PubMed  Google Scholar 

  67. Kumar SM, Yu H, Fong D, Acs G, Xu X. Erythropoietin activates the phosphoinositide 3-kinase/Akt pathway in human melanoma cells. Melanoma Res. 2006;16(4):275–83.

    Article  CAS  PubMed  Google Scholar 

  68. Kumar SM, Acs G, Fang D, Herlyn M, Elder DE, Xu X. Functional erythropoietin autocrine loop in melanoma. Am J Pathol. 2005;166(3):823–30.

    Article  CAS  PubMed  Google Scholar 

  69. Lai SY, Grandis JR. Understanding the presence and function of erythropoietin receptors on cancer cells. J Clin Oncol. 2006;24(29):4675–6.

    Article  PubMed  Google Scholar 

  70. Begg CB, Berlin JA. Publication bias: a problem in interpreting medical data. J R Stat Soc A. 1988;151:419–63.

    Article  Google Scholar 

Download references

Conflicts of interest

None.

Author information

Authors and Affiliations

  1. State Key Laboratory of Reproductive Medicine, Department of Breast Surgery, Nanjing Maternity and Child Health Care Hospital Affiliated to Nanjing Medical University, Nanjing, 210004, China

    Sheng Gao, Jing-Jing Ma & Cheng Lu

Authors
  1. Sheng Gao
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jing-Jing Ma
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Cheng Lu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Cheng Lu.

Additional information

S. Gao and J. Ma contributed equally to this work and should be considered as co-first authors.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gao, S., Ma, JJ. & Lu, C. Venous thromboembolism risk and erythropoiesis-stimulating agents for the treatment of cancer-associated anemia: a meta-analysis. Tumor Biol. 35, 603–613 (2014). https://doi.org/10.1007/s13277-013-1084-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-013-1084-5

Keywords

Search

Navigation